Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Establishment Labs Holdings Inc. ESTA

Healthcare  —  Medical Devices
65.97 0.39 0.59% as of 25 Sep
Market cap
$2.0B
P/E
0.0×
Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Establishment Labs Holdings Inc. (ESTA) Business Profile

Updated before January 2025

Company Overview

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company specializing in advanced breast aesthetics and reconstruction solutions. Founded in 2004 by Juan José Chacón-Quirós, the company is headquartered in Alajuela, Costa Rica. Establishment Labs has emerged as a leader in the breast implant industry, leveraging innovative technologies and a commitment to patient safety and satisfaction. The company’s leadership team includes Juan José Chacón-Quirós as CEO, Raj Denhoy as CFO, and several other experienced executives who bring expertise in medical technology, global operations, and strategic growth.

Core Business Segments

Breast Aesthetics and Reconstruction

Establishment Labs’ primary focus is on breast aesthetics and reconstruction. The company’s flagship product line, Motiva Implants®, is known for its advanced safety features, innovative design, and superior patient outcomes. Motiva Implants® are available in over 80 countries and are recognized for their unique features, such as the SmoothSilk®/SilkSurface® technology and the BluSeal® indicator, which enhance safety and durability.

Digital Health and Patient Engagement

The company also offers digital health solutions aimed at improving patient engagement and outcomes. Through its MotivaImagine® platform, Establishment Labs provides tools for surgeons and patients to visualize and plan procedures, ensuring a personalized and informed approach to breast aesthetics.

Research and Development

Establishment Labs invests heavily in R&D to drive innovation in medical technology. The company is actively developing new products and technologies, including minimally invasive solutions for breast aesthetics and reconstruction, as well as expanding its portfolio to address unmet needs in the market.

Business Model

Establishment Labs operates a vertically integrated business model, encompassing product design, manufacturing, and distribution. The company generates revenue primarily through the sale of its Motiva Implants® and related products. By maintaining control over its supply chain and leveraging advanced manufacturing processes, Establishment Labs ensures high-quality products and cost efficiency. Additionally, the company’s digital health solutions and patient engagement tools create a recurring revenue stream and strengthen its relationship with both surgeons and patients.

Strategic Direction

Establishment Labs is focused on expanding its global footprint and increasing market share in the breast aesthetics and reconstruction industry. Key strategic initiatives include:

  • Geographic Expansion: The company is targeting growth in emerging markets, particularly in Asia and Latin America, where demand for breast aesthetics is increasing.
  • Product Innovation: Establishment Labs is developing new products, such as minimally invasive solutions and next-generation implants, to address evolving patient needs.
  • Sustainability Goals: The company is committed to sustainability, with initiatives aimed at reducing its environmental impact and promoting ethical practices across its operations.
  • Regulatory Approvals: Establishment Labs is working to secure regulatory approvals in key markets, including the United States, to expand access to its products.

Competitive Landscape

Establishment Labs operates in a competitive market, facing competition from both established players and emerging companies in the medical aesthetics industry. Key competitors include:

  • Allergan (AbbVie): A leading provider of breast implants and other medical aesthetics products.
  • Sientra, Inc.: A U.S.-based company specializing in breast implants and related products.
  • Mentor Worldwide LLC (Johnson & Johnson): A global leader in breast implant technology.

Despite the competition, Establishment Labs differentiates itself through its innovative product offerings, commitment to safety, and strong global presence.

Risk Factors

While Establishment Labs has demonstrated strong growth, it faces several risks, including:

  • Market Dependence: The company’s revenue is heavily reliant on the sale of breast implants, making it vulnerable to market fluctuations and changes in consumer preferences.
  • Regulatory Challenges: Obtaining and maintaining regulatory approvals in various markets can be time-consuming and costly.
  • Supply Chain Disruptions: As a vertically integrated company, Establishment Labs is exposed to risks related to supply chain disruptions, which could impact production and delivery timelines.
  • Competition: Intense competition in the medical aesthetics industry could pressure pricing and market share.

Recent Developments

In recent years, Establishment Labs has achieved several milestones:

  • Product Launches: The company introduced new products, including the Motiva Flora® tissue expander, designed to improve outcomes in breast reconstruction.
  • Regulatory Approvals: Establishment Labs received CE Mark approval for its Motiva Implants® in Europe and is pursuing FDA approval in the United States.
  • Strategic Partnerships: The company has formed partnerships with leading medical institutions and organizations to advance research and education in breast aesthetics.
  • Global Expansion: Establishment Labs has expanded its presence in key markets, including Asia and Latin America, through strategic distribution agreements and marketing initiatives.

Investment Considerations

Strengths

  • Innovative Products: Establishment Labs’ Motiva Implants® are recognized for their advanced safety features and superior design.
  • Global Presence: The company operates in over 80 countries, providing a strong foundation for growth.
  • Commitment to R&D: Establishment Labs invests heavily in research and development, driving innovation and maintaining a competitive edge.

Risks

  • Regulatory Uncertainty: Delays in obtaining regulatory approvals could impact growth prospects.
  • Market Dependence: Reliance on breast implant sales makes the company vulnerable to market fluctuations.
  • Competitive Pressure: Intense competition in the medical aesthetics industry could affect pricing and profitability.

Conclusion

Establishment Labs Holdings Inc. is a leading player in the breast aesthetics and reconstruction industry, known for its innovative products and commitment to patient safety. With a strong global presence, a focus on R&D, and strategic initiatives aimed at expanding its market share, the company is well-positioned for future growth. However, investors should consider the risks associated with regulatory challenges, market dependence, and competition when evaluating Establishment Labs as a potential investment opportunity.